Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 20/20 | 0.56 |
| ▸ | S1PR4 | O95977 | 3/20 | 0.56 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.51 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2168010 | 0.97 | S1PR1 (0.56) | S1PR1S1PR4S1PR5ADORA3S1PR3 | |
| SCHEMBL3848805 | 0.84 | S1PR1 (0.54) | S1PR1S1PR4S1PR5ADORA3S1PR3 | |
| SCHEMBL3855566 | 0.83 | S1PR1 (0.56) | S1PR1S1PR4S1PR5ADORA3S1PR3 | |
| SCHEMBL3847474 | 0.82 | S1PR1 (0.57) | S1PR1S1PR4S1PR5ADORA3S1PR3 | |
| SCHEMBL3848347 | 0.82 | S1PR1 (0.55) | S1PR1S1PR4S1PR5ADORA3S1PR3 | |
| SCHEMBL2180656 | 0.82 | S1PR1 (0.55) | S1PR1 | |
| SCHEMBL13980737 | 0.82 | S1PR1 (0.53) | S1PR1S1PR5S1PR3 | |
| SCHEMBL2178316 | 0.81 | S1PR1 (0.54) | S1PR1S1PR4S1PR5 | |
| SCHEMBL3853824 | 0.81 | S1PR1 (0.54) | S1PR1S1PR4S1PR5ADORA3S1PR3 | |
| SCHEMBL13713803 | 0.81 | S1PR1 (0.56) | S1PR1S1PR4S1PR5ADORA3S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1644367-B1 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | NOVARTIS AG (CH) | 2015-10-14 | — | — | EP | claimed |
| JP-4728962-B2 | — | — | 2011-07-20 | — | — | JP | claimed |
| EP-1644367-A4 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2008-12-31 | — | — | EP | claimed |
| US-7462629-B2 | Immunosuppressant compounds and compositions | IRM LLC (BM) | 2008-12-09 | — | — | US | claimed |
| JP-2007501860-A | — | — | 2007-02-01 | — | — | JP | claimed |
| EP-1644367-A1 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2006-04-12 | — | — | EP | claimed |
| US-20050009786-A1 | Immunosuppressant compounds and compositions | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2005-01-13 | — | — | US | claimed |
| WO-2004113330-A1 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2004-12-29 | — | — | WO | claimed |
| EP-1644367-B1 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | NOVARTIS AG (CH) | 2015-10-14 | — | — | EP | disclosed |
| EP-1644367-A4 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2008-12-31 | — | — | EP | disclosed |
| US-7462629-B2 | Immunosuppressant compounds and compositions | IRM LLC (BM) | 2008-12-09 | — | — | US | disclosed |
| US-7462629-B2 | Immunosuppressant compounds and compositions | IRM LLC (BM) | 2008-12-09 | — | — | US | disclosed |
| US-7462629-B2 | Immunosuppressant compounds and compositions | IRM LLC (BM) | 2008-12-09 | — | — | US | disclosed |
| EP-1644367-A1 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2006-04-12 | — | — | EP | disclosed |
| US-20050009786-A1 | Immunosuppressant compounds and compositions | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2005-01-13 | — | — | US | disclosed |
| WO-2004113330-A1 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009786-A1 | Immunosuppressant compounds and compositions | ICOS, EDNRA, NFATC1 | S1PR1 133/4885S1PR4 211/4885S1PR5 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.